Medivir

A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Öresundsdagen Lund den 16 September 2013


Rein Piir, EVP Corporate Affairs & IR

Medivir - the emerging European pharma company

- Integrated pharma company with 15 marketed Rx pharmaceuticals in the Nordics - annual sales of ~170 MSEK with an EBITDA of ~75 MSEK
- First in-house developed pharmaceutical (Xerclear) on the market the second is approaching market (Simeprevir)
- Strong position in HCV drug development. Simeprevir, in partnership with Janssen, is considered best in class protease inhibitor filed in Japan, the US and Europe in H1, 2013
- World leading expertise in polymerase and protease drug targets
- Extensive partnership track record with major global pharma companies
- Solid financial position (400 MSEK on July 1)










P&L and quarterly pharmaceutical sales

(SEK m)	2013 Jan-June	2012 Jan-June	2012 Jan-Dec
Net turnover	218.8	85.2	170.6
Gross profit	183.8	54.1	109.3
EBITDA	43.6	-79.6	-165.3
EBIT	14.7	-99	, -201.3
Profit/loss before tax	14.5	-98.4	-210.8
Profit/loss after tax	7.5	-107.2	-234.1

Annual net burn rate is ~200 MSEK, excluding milestone and royalty payments







R&D pipeline status

			Preclinical phase		Clinical phase				
Field	Project	Partner	Re- search	Deve- lopment	Phase I	Phase Ila	Phase IIb	Phase III	Market

Anivirals

Labial herpes	Xerclear (Zoviduo, Zovirax Duo)	GlaxoSmithKline (GSK)				
Hepatitis C	Simeprevir (TMC435), NS3 protease inhibitor	Janssen Pharmaceuticals				
Hepatitis C	NS5B nucleotide-based polymerase inhibitor	Janssen Pharmaceuticals				
Hepatitis C	NS5B nucleotide-based polymerase inhibotor	Unpartnered				
HIV	Protease inhibitor	Janssen Pharmaceuticals				

Other indications

Bone related disorders	Cathepsin K inhibitor	Unpartnered				
Neuropathic pain	Cathepsin S inhibitor	Unpartnered				



Simeprevir

- A potent HCV protease inhibitor in registration phase

Simeprevir - phase III development program in HCV G1 & 4 infected patients

- o QUEST 1 and 2 (treatment-naïve) final data presented at EASL
- **PROMISE** (prior relapser) final data presented at Digestive Week
- CONCERTO 1-4 in Japan (treatment naïve & experienced) results presented at Japan Society of Hepatology's Annual Meeting

Ongoing phase III studies:

- China: naive GT1 HCV patients fully enrolled (n=444)
- **ATTAIN:** prior non-responders (SMV vs TVR) *fully enrolled (n=765)*
- **RESTORE:** HCV GT4 infected patients *fully enrolled (n=107)*
- C212: HIV-HCV co-infected patients fully enrolled (n=109)
- 12 weeks full stop, open-label, single-arm study in treatment naïve GT1 patients recruitment ongoing




Simeprevir - Regulatory status and summary phase III

Regulatory applications filed in:

- Japan for hepatitis C genotype 1, naïve, prior non-responders or relapsed February, 2013
- US for hepatitis C genotype 1 Priority Review granted in May, 2013
- EU for hepatitis C genotype 1 and 4 April, 2013

Excellent efficacy, safety and tolerability


- ~80 % overall cure rates (up to 91% of patients could stop all treatment at 24 weeks)
- Overall incidence of adverse events similar to placebo



**SVR12; Sustained Virologic Response 12 weeks (cure rate) *P/R: Peginterferon/ribavirin



Three major targets in hepatitis C virus






Long term objective - eradication of hepatitis C




The evolution in treating hepatitis C will expand the market value, number of patients treated and regions over the next 10-15 years

Market value, peak sales >20 BUSD

Value/Patients treated



Simeprevir in interferon-free combinations



IFN-free therapies







Once-daily regimen of simeprevir plus sofosbuvir with or without ribavirin in hard to cure HCV patients *

*The COSMOS study: COmbination of SiMeprevir and sOfosbuvir in HCV infected patientS


COSMOS study – Summary of Interim Results: Efficacy

Efficacy results with simeprevir (SMV) and sofosbuvir (SOF) once daily for 12 weeks with or without ribavirin (RBV).

	Co	hort 1	Cohort 2			
		<u>nder </u> HCV patients score F0-F2)	Prior <u>null</u> responder and treatment <u>naïve</u> HCV patients (<u>METAVIR scores F3 or F4</u>)			
	SMV / SOF+ RBV	SMV / SOF	SMV / SOF + RBV	SMV / SOF		
	(n=27)	(n=14)	(n=27)	(n=14)		
SVR4	26/27 (96%)	13/14 (93%)	26/27 (96%)	14/14 (100%)		
SVR8	26/27 (96%)	13/14 (93%)	-	-		

• Interim results indicate high efficacy in hardest to cure HCV patients

• Once-daily simeprevir and sofosbuvir was generally safe and well tolerated





Value proposition – the road towards profitability



(2

Innovative portfolio will evolve over time


- World class expertise in polymerase and protease drug targets
- Commitment towards targets in infectious diseases
- New therapeutic areas based on core competence
- Partner of choice for pharmaceuticals and development programs

Long term commitment in the HCV area

- Simeprevir, partnered with Janssen Pharmaceuticals
 - Regulatory files submitted in EU, US and Japan
 - Ongoing interferon-free combination trials will guide treatment opportunities
- In-house unpartnered HCV nucleotide-based polymerase inhibitor program can offer new combination treatment opportunities



Value proposition – the road towards profitability



Commercial presence in the Nordic region creates revenue

- 15 solid Rx pharmaceuticals with annual sales of ~170 MSEK
 Commercial platform for the Nordic launch of simeprevir in 2014
 Expansion of product partfalia
- Expansion of product portfolio



External perspective

- Top ranked as a listed company
- Profitable and fast growing Nordic based pharmaceutical company



Key events in the coming 12 month



- H2-13 Results from phase I-study with MIV-711, our cathepsin K inhibitor (bone related disorders)
- H2-13 Start of the phase II study HELIX-2 (simeprevir + TMC647055 and samatasvir IDENIX)
- H2-13 Start of Phase II with simeprevir and VX-135 (Vertex)
- H2-13 Potential CD selection in Cathepsin S (neuropathic pain) program
- H2-13 Goal to start phase I trials with Medivir/Janssen nucleotide NS5B-inhibitor
- H2-13 Presentations at AASLD
- H2-13 SVR data from phase II Cosmos study with simeprevir and sofosbuvir
- H2-13 Anticipated approval in Japan for simeprevir
- H2-13 Anticipated approval of simeprevir in the US
- H2-13 Data from the phase II combination study with simeprevir and daclatasvir (BMS)
- H1-14 Anticipated approval of simeprevir (triple) in EU
- H1-14 Presentations at EASL
- H1-14 Potential CD selection in our internal Nucleotide NS5B inhibitor program



www.medivir.com

Ticker: MVIR Exchange: OMX / NASDAQ

For more information please contact Rein Piir, EVP Corporate Affairs & IR (rein.piir@medivir.com)

